Ono Pharmaceutical ADR Representing 1/3rd Ord Shs (OPHLY) – aksjekurser og nyheter

Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka. Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948. Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen. Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb. In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia

Om Ono Pharmaceutical ADR Representing 1/3rd Ord Shs

Administrerende direktørGyo Sagara | Gyo Sagara

Ansatte4,21k

Grunnlagt1717

HovedkontorOsaka, Osaka, Japan

Sektor-

Nettstedono-pharma.com

Alle verdier i JPY	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	129,60 mrd.	139,90 mrd.	118,75 mrd.	116,16 mrd.
Varekostnad	34,96 mrd.	36,68 mrd.	33,06 mrd.	28,68 mrd.
Direkte driftskostnader	34,96 mrd.	36,68 mrd.	33,06 mrd.	28,68 mrd.
Utgifter til forskning og utvikling	34,77 mrd.	33,53 mrd.	42,49 mrd.	32,40 mrd.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	30,08 mrd.	31,73 mrd.	27,70 mrd.	23,90 mrd.
Driftskostnader	64,56 mrd.	67,00 mrd.	77,09 mrd.	56,83 mrd.
Totale driftskostnader	99,53 mrd.	103,68 mrd.	110,15 mrd.	85,51 mrd.
Driftsinntekter	30,07 mrd.	36,22 mrd.	8,60 mrd.	30,65 mrd.
Andre ikke-operasjonelle inntekter	-	-	318,00 mill.	−2,00 mill.
EBT inkludert uvanlige elementer	29,52 mrd.	37,20 mrd.	3,28 mrd.	31,25 mrd.
EBT uten uvanlige elementer	29,52 mrd.	37,20 mrd.	8,77 mrd.	31,25 mrd.
Kostnad for inntektsskatt	7,17 mrd.	8,31 mrd.	2,24 mrd.	7,09 mrd.
Faktisk avgiftssats	24,30 %	22,35 %	68,23 %	22,68 %
Andre driftskostnader	−291,00 mill.	1,73 mrd.	3,81 mrd.	526,00 mill.
Nettoinntekt	22,42 mrd.	28,86 mrd.	818,00 mill.	24,15 mrd.
Netto fortjenestemargin	17,30 %	20,63 %	0,69 %	20,79 %
Resultat per aksje	-	-	-	-
Rente- og investeringsinntekter	677,00 mill.	1,39 mrd.	195,00 mill.	1,38 mrd.
Rentekostnader	−1,23 mrd.	−408,00 mill.	−34,00 mill.	−783,00 mill.
Netto rentekostnader	−549,00 mill.	979,00 mill.	161,00 mill.	598,00 mill.
Avskrivnings- og amortiseringskostnader	-	-	3,10 mrd.	-
EBITDA	39,39 mrd.	45,82 mrd.	18,21 mrd.	39,63 mrd.
Gevinst eller tap ved salg av eiendeler	-	-	2,20 mrd.	-

Finance

Spør om hva som helst